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Abstract
Although molecular biology studies indicate the presence of adenosine A2A receptors in the rat hippocampus, the pharmacological
characterization of adenosine A2A receptor binding and of its putative facilitatory effects has revealed features essentially different from these
found for adenosine A2A receptors in most preparations. We now confirmed that activation of adenosine A2A receptors with 2-[4-(2-p-
carboxyethyl)phenylamino]-5V-N-ethylcarboxamidoadenosine (CGS 21680, 1-30 nM) or 2-hexynyl-5V-N-ethylcarboxamidoadenosine
(HENECA, 3–100 nM) facilitated the veratridine-evoked [3H]acetylcholine release from hippocampal synaptosomes with a maximal
effect of 14F 2% and 16F 2%, respectively. These effects were prevented by the adenosine A2A receptor antagonists, 4-(2-[7-amino-2-{2-
furyl}{1,2,4}triazolo{2,3a}{1,3,5}triazin-5-yl-amino]ethyl)phenol (ZM 241385, 20 nM) and 5-amino-7-(2-phenylethyl)-2-(2-furyl)-
pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261, 20 nM), but not by the adenosine A1 receptor antagonist, 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX, 20 nM). Adenosine A2A receptors may activate adenylate cyclase and protein kinase A since CGS 21680 (10
nM) facilitation of [3H]acetylcholine release was occluded by 8-bromo-cAMP (0.5 mM) and forskolin (10 AM) and prevented by H-89 (1
AM), but unaffected by phorbol-12,13-didecanoate (250 nM) or bisindolylmaleimide I (1 AM). The existence of adenosine A2A receptors in
hippocampal nerve terminals was further confirmed by a Western blot immunoreactivity qualitatively identical to that found in the striatum.
This constitutes the first pharmacological identification of canonical adenosine A2A receptors coupling to the expected cAMP/protein kinase
A pathway in the hippocampus with the expected immunoreactivity.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Adenosine can either decrease or facilitate the evoked
release of neurotransmitters in the nervous system by
activating inhibitory adenosine A1 or facilitatory adenosine
A2A receptors, respectively (Cunha, 2001). As occurs for the
modulation of glutamate (Ambro´sio et al., 1997; Lopes et
al., 2002) and serotonin release (Okada et al., 2001), the
modulation of acetylcholine release by adenosine in the
hippocampus is also controlled by both adenosine A1 and
A2A receptors (Cunha et al., 1994a; Jin and Fredholm,
1997). The presence of adenosine A2A receptors in the
hippocampus has been confirmed using molecular biology
studies, like polymerase chain reaction (PCR), in situ
hybridization (Cunha et al., 1994b) and Northern blot
analysis (Peterfreund et al., 1996), but binding studies have
revealed an atypical binding pattern (Cunha et al., 1996) and
G protein coupling (Cunha et al., 1999) of these putative
adenosine A2A receptors. Some functional peculiarities of
the facilitatory effects of the prototypical adenosine A2A
receptor agonist, CGS 21680 (Fredholm et al., 1994),
include the strict dependency on co-activation of adenosine
A1 receptors in the control of glutamate release (Lopes et al.,
2002), the atypical pharmacology in the control of GABA
release (Cunha and Ribeiro, 2000a) and the coupling to
protein kinase C in the control of excitatory synaptic trans-
mission (Cunha and Ribeiro, 2000b; Lopes et al., 2002).
Thus, none of the neurotransmitter systems controlled by
putative adenosine A2A receptors has yet proven to obey to a
clear and typical adenosine A2A receptor pharmacology and
to be coupled to the postulated cAMP/protein kinase A
transducing pathway (Fredholm et al., 1994).
We now report that the control by adenosine A2A
receptors of acetylcholine release from hippocampal nerve
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terminals obeys to the expected pharmacology for adenosine
A2A receptors (antagonism by ZM 241385 and SCH 58261
but not by DPCPX) and requires the activation of the
adenylate cyclase/cAMP/protein kinase A pathway rather
than the protein kinase C transducing pathway.
2. Materials and methods
2.1. Drugs and solutions
8-Bromoadenosine-3V:5V-cyclic monophosphate (8-
bromo-cAMP), hemicholinium-3, 7ß-deacetyl-7ß-(g-N-
methylpiperazino)butyrylforskolin (forskolin), veratridine
and 1,9-dideoxyforskolin were from Sigma; 2-[4-(2-p-car-
boxyethyl)phenylamino]-5V-N-ethylcarboxamidoadenosine
(CGS 21680), phorbol-12,13-didecanoate and 1,3-dipropyl-
8-cyclopentylxanthine (DPCPX) were from RBI; H-89 and
bisindolylmaleimide were from Calbiochem; 4-(2-[7-
amino-2-{2-furyl}{1,2,4}triazolo{2,3a}{1,3,5}triazin-5-
yl-amino]ethyl)phenol (ZM 241385) was from Tocris;
and [methyl-3H]choline (specific activity 41.3 Ci/mmol)
was from Amersham. Rolipram [4-(3V-cyclopentyloxy-
4V-methoxyphenyl)-2-pyrrolidone (4-RS)] was a gift of
Schering; 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-
[4,3-e]-1,2,4 triazolo[1,5-c]pyrimidine (SCH 58261) was
provided by E. Ongini (Schering Plough, Milan); 2-hex-
ynyl-5V-N-ethylcarboxamidoadenosine (HENECA) was
offered by G. Cristalli (Univ. Camerino, Italy); and goat
purified IgG anti-adenosine A2A receptor antibody (200
Ag/ml) was from Santa Cruz Biotechnology-Europe. All
other reagents were of the highest purity available.
Forskolin was made up to a 20 mM stock solution in
ethanol. Dideoxyforskolin was made up to a 20 mM and
rolipram in a 50 mM stock solution in dimethylsulfoxide.
CGS 21680, HENECA, ZM 241385, SCH 58261, phorbol-
12,13-didecanoate, H-89 and bisindolylmaleimide were
made up into 5 mM stocks in dimethylsulfoxide. DPCPX
was made up into a 5 mM stock in 99% dimethylsulfoxide–
1% NaOH (1 M) (v/v). Aqueous dilution of these stock
solutions was made daily.
2.2. [3H]acetylcholine release from nerve terminals
The release of [3H]acetylcholine from a synaptosomal
fraction from the rat hippocampus was carried out as
previously described (Cunha et al., 1995) using male Wistar
rats (130–140 g) decapitated after anesthesia under halo-
thane atmosphere, following the European Union guidelines
for handling experimental animals. Briefly, the synapto-
somes were equilibrated for 10 min at 37 jC, loaded with
[3H]choline (10 ACi/ml, 0.125 AM), layered over Whatman
GF/C filters into 90-Al chambers and superfused at a flow
rate of 0.6 ml/min with a gassed (95% O2 and 5% CO2)
Krebs solution of the following composition: NaCl 125 mM,
KCl 3 mM, NaH2PO4 1 mM, NaHCO3 25 mM, CaCl2 1.5
mM, MgSO4 1.2 mM, glucose 10 mM and hemicholinium-3
0.01 mM (see Cunha et al., 1995). After a 30-min washout
period, the synaptosomes were stimulated with veratridine
(10 AM) for 2 min, at 6 and 26 min after starting sample
collection (S1 and S2). At the end of the experiments, the
filters were removed from the chambers to determine the
amount of tritium retained by the synaptosomes. At least 12
h after addition of 5 ml of scintillation cocktail (Scintran T,
BDH) to each of the 2-min effluent samples and to the filters,
scintillation counting was performed with a 55–60% effi-
ciency during 2 min. The fractional release of tritium was
expressed in terms of percentage of total radioactivity
present in the tissue at the time of sample collection. The
release of tritium evoked by each veratridine pulse, i.e. the
evoked release, was calculated by integration of the area of
the peak upon subtraction of the estimated basal tritium
outflow from the total outflow of tritium due to stimulation.
To measure [3H]actylcholine in the total tritium outflow,
[3H]acetylcholine was separated using a cation exchanger,
tetraphenylboron, after phosphorylation of [3H]choline, as
previously described (Cunha et al., 1994a).
When the effect of drugs on the release of acetylcholine
was investigated, these drugs were added to the superfusion
medium 6 min before S2, i.e. 20 min after starting sample
collection, and remained in the bath up to the end of the
experiment. The effect of these drugs on the evoked release
of acetylcholine was expressed by alterations of the ratio
between the evoked release due to second stimulation period
and the evoked release due to the first stimulation period
(S2/S1 ratio). This ratio is remarkably constant in between
experiments, in contrast to absolute values of S1 that vary in
between experiments, precluding a reliable analysis of this
parameter. When we evaluated the modifications of the
effect of these drugs by modifiers, the modifiers were
applied 15 min before starting sample collection and hence
were present during S1 and S2. When present during S1 and
S2, none of the modifiers (ZM 241385, SCH 58261,
DPCPX, 8-Br-cAMP, forskolin, dideoxyforskolin, rolipram,
H-89, bisindolylmaleimide or phorbol-12,13-didecanoate),
significantly altered (P>0.05) the S2/S1 as compared to the
S2/S1 ratio obtained in the absence of the modifiers (data not
shown).
The values are presented as meanF S.E.M. The percent-
age effect of drugs was calculated in each individual experi-
ment and the S.E.M. is relative to the variance of this
percentage effect. To test the significance of the effect of
drugs versus control, a paired Student’s t test was used. When
making comparisons from a different set of experiments with
control, a one-way analysis of variance (ANOVA) was used,
followed by Dunnett’s test. P < 0.05 was considered to
represent a significant difference.
2.3. Western blot analysis of A2A receptors
The analysis of adenosine A2A receptor immunoreactiv-
ity was carried out in whole membranes of the striatum and
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in membranes from a Percoll-purified synaptosomal fraction
of the hippocampus, prepared as previously described (e.g.
Cunha et al., 1996). After determining the amount of protein
(Spector, 1978), each sample was diluted with two volumes
of a solution containing 8 M urea, 100 mM dithiothreitol,
2% (w/v) sodium dodecyl sulfate and 375 mM Tris–HCl
pH 6.8 and incubated for 2 h at 37 jC. These diluted
samples and the pre-stained molecular weight markers
(Amersham) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (10% with a 4% con-
centrating gel) under reducing conditions (Laemmeli, 1970)
and electro-transferred to polyvinylidene difluoride mem-
branes (0.45 Am from Amersham). After blocking for 2 h at
room temperature with 5% milk in Tris-buffered saline, pH
7.6 containing 0.1% Tween 20 (TBS-T), the membranes
were incubated overnight at 4 jC with the anti-adenosine
A2A receptor antibody (1:100 dilution). After four washing
periods for 10 min with TBS-T containing 0.5% milk, the
membranes were incubated with the alkaline phosphatase-
conjugated anti-goat secondary antibody (1:2000 dilution
from Calbiochem) in TBS-T containing 1% milk during 90
min at room temperature. After five 10-min washes in TBS-
T 0.5% milk, the membranes were incubated with Enhanced
Chemi-Fluorescent during 5 min and then analysed with a
Storm (Molecular Devices).
3. Results
3.1. Pharmacological characterization of facilitatory ad-
enosine A2A receptors in hippocampal cholinergic nerve
terminals
The two selective adenosine A2A receptor agonists, CGS
21680 and HENECA (1–100 nM) (Fredholm et al., 1994),
facilitated the evoked release of acetylcholine from hippo-
campal nerve terminals (Fig. 1A), as previously described
(Cunha et al., 1995, 1997). The concentration-dependent
curve for the facilitation of the evoked release of acetylcho-
line was similar for the two agonists, with increasing effects
with increasing applied concentrations of the agonist, CGS
21680 being slightly more potent than HENECA (Fig. 1A).
Also, for both agonists, there was a decreased facilitation of
the evoked release of acetylcholine at the highest concen-
trations of the agonists tested that may either result from an
adenosine A2A receptor-induced desensitization (see Cunha,
2001 for discussion) or from a loss of selectivity towards
inhibitory adenosine A1 receptors (see, e.g. Lupica et al.,
1990).
Previous studies by our group had already tentatively
characterized this facilitatory effect of acetylcholine release
by CGS 21680 and HENECA as being mediated by adeno-
sine A2A receptors based on the efficiency of the adenosine
A2A receptor antagonists, CSC (8-(3-chlorostyryl)caffeine)
and of ZM 241385, to prevent these effects (Cunha et al.,
1995, 1997). However, some studies have cast doubts on the
real selectivity of CSC and of ZM 241385 (Cunha et al.,
1996; de Mendonca and Ribeiro, 1994; Lindstro¨m et al.,
1996; Lopes et al., 1999a) towards adenosine A1 receptor-
mediated responses. Thus, we decided to test the ability of
SCH 58261 to antagonize the CGS 21680- and HENECA-
induced facilitation of acetylcholine release, since this
compound has repeatedly been shown to behave as a
selective antagonist of adenosine A2A receptors (Cunha et
al., 1999; Fredholm et al., 1998; Lindstro¨m et al., 1996). As
illustrated in Fig. 1B, the facilitatory effects of either CGS
21680 (30 nM) or HENECA (30 nM) were nearly abolished
in the presence of SCH 58261 (20 nM) and were virtually
Fig. 1. Concentration-dependent facilitation by the adenosine A2A receptor
agonists, CGS 21680 and HENECA, of the evoked release of [3H]ace-
tylcholine ([3H]ACh) from rat hippocampal synaptosomes (A), and
comparison of the efficiency of the adenosine A1 and A2A receptor
antagonists, DPCPX and SCH 58261, to antagonize this adenosine A2A
receptor-mediated facilitation of [3H]ACh release (B). The superfused nerve
terminals (142F 8 Ag protein per chamber) were stimulated twice (S1 and
S2) with veratridine (10 AM). The evoked tritium release was Ca2 +
-dependent (74%) and mainly constituted by [3H]ACh (for details see Cunha
et al., 1997), and was assumed to represent exocytotic ACh release.
HENECA or CGS21680 were added 7 min before S2 and remained in the
bath up to the end of the experiment. The facilitatory effects of HENECA or
CGS21680 were calculated from the alteration of the S2/S1 ratio compared
with the S2/S1 ratio in the absence of these adenosine A2A receptor agonists.
*P < 0.05 compared with 0%. In (B), the drugs were present either during S2
(added 7 min before S2) or in S1 and S2 (added 15 min before starting
sample collection) as indicated by the symbols below each column. SCH
58261 (20 nM) or DPCPX (20 nM) when present during S1 and S2 did not
modify the S2/S1 ratio compared with control. *P < 0.05 compared with the
effect of CGS 21680 (30 nM, first bar from the left), **P< 0.05 compared
with the effect of HENECA (30 nM, forth column from the left). The results
are meanF S.E.M. of three to four experiments in (A) and (B).
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unaffected by the adenosine A1 receptor antagonist, DPCPX
(20 nM).
So far, we have only been able to show that activation of
adenosine A2A receptors with selective adenosine A2A
receptor agonists triggered a facilitation of acetylcholine
release with a pharmacology compatible with the activation
of adenosine A2A receptors. We then sought to demonstrate
that a facilitatory response could be obtained with non-
selective adenosine receptor ligands. It is difficult to use
adenosine itself to carry out a pharmacological character-
ization of adenosine receptor-mediated effects since adeno-
sine is rapidly taken up and metabolized by virtually all
eukaryotic cell types. Thus, we tested the effect of the
closest chemical analogue of adenosine, 2-chloroadenosine,
which is less prone to uptake and metabolism and activates
all adenosine receptor subtypes (Fredholm et al., 1994). As
illustrated in Fig. 2A, 2-chloroadenosine (10 AM) inhibited
the evoked release of acetylcholine, in accordance with
previous observations in hippocampal slices (Cunha et al.,
1994a). This inhibitory effect was abolished by the adeno-
sine A1 receptor selective antagonist, DPCPX (20 nM),
indicating that it is an adenosine A1 receptor-mediated
effect. In the presence of DPCPX (20 nM), we now
observed that 2-chloroadenosine facilitated the evoked
release of acetylcholine (Fig. 2B). This facilitatory effect
was prevented by SCH 58261 (20 nM), indicating that it is
mediated by facilitatory adenosine A2A receptors (Fig. 2C).
These results show that the evoked release of acetylcholine
is under the control of both inhibitory A1 and facilitatory
A2A receptors, and that the exogenous addition of a non-
selective adenosine receptor agonist mainly leads to the
activation of inhibitory adenosine A1 rather than of facili-
tatory adenosine A2A receptors.
3.2. Transducing system operated by facilitatory adenosine
A2A receptors in hippocampal cholinergic nerve terminals
Classically, adenosine A2A receptors are recognized as
being coupled to the adenylate cyclase/cAMP transducing
pathway (Fredholm et al., 1994). However, several eviden-
ces indicate that some facilitatory effects triggered by the
prototypical adenosine A2A receptor agonist, CGS 21680, in
low nanomolar concentrations, are dependent on protein
kinase C activation (Cunha and Ribeiro, 2000a,b; Lopes et
al., 2002). We first tested the effect of the direct activation of
protein kinase A and of protein kinase C on acetylcholine
release. The direct activation of protein kinase C with its
direct cell-permeable activator phorbol-12,13-didecanoate
(250 nM) facilitated the evoked release of acetylcholine
by 13.1F 2.2% (n = 4). As illustrated in Fig. 3, the protein
kinase C inhibitor, bisindolylmaleimide (1 AM), signifi-
cantly attenuated this facilitatory effect of phorbol-12,13-
didecanoate, indicating that it was indeed due to protein
kinase C activation (n = 4). The direct activation of protein
kinase A with its direct cell-permeable activator 8-bromo-
cyclic AMP (8-Br-cAMP, 0.5 mM) facilitated the evoked
release of acetylcholine by 21.2F 3.4% (n = 4). As illus-
trated in Fig. 3, the protein kinase A inhibitor, H-89 (1 AM),
completely prevented this facilitatory effect of 8-Br-cAMP,
indicating that it was indeed due to protein kinase A
Fig. 2. Inhibition by 2-chloroadenosine (CADO, the closest chemical
analogue of adenosine) of the evoked release of acetylcholine (ACh) from
rat hippocampal nerve terminals (A), and reversal of this effect upon
blockade of adenosine A1 receptors with DPCPX (B) that is prevented by
the adenosine A2A receptor antagonist, SCH 58261 (C). In A and B are
shown the time course of [3H]ACh release, measured as the fractional
release that is expressed in terms of the percentage of total radioactivity
present in the preparation at the beginning of the collection of each sample.
The preparation was challenged with two periods of stimulation with 10 AM
veratridine (S1 and S2), as indicated by the bars above the abscissa. The
open symbols represent [3H]ACh release from a control chamber, to which
no drug was added in (A) or that were in the presence of DPCPX (20 nM)
from 15 min before starting sample collection onwards in (B), and the filled
symbols represent [3H]ACh release of the test chamber, to which CADO
(10 AM) was added through the superfusate, as indicated by the upper bar.
In (C) are shown the average modulatory effects of CADO (10 AM) in the
absence or in the presence of DPCPX (20 nM) and of SCH 58261 (20 nM)
as indicated by the symbols below each bar. *P< 0.05. The results are
meanF S.E.M. of four experiments.
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activation (n = 4). In accordance with previous suggestions
that high micromolar concentrations of 8-Br-cAMP might
trigger the activation of inhibitory A1 receptors (e.g. Dun-
widdie and Hoffer, 1980; Brundege et al., 1997), it was
observed that 8-Br-cAMP (0.5 mM) in the presence of H-89
(1 AM) now inhibited the evoked release of acetylcholine
(Fig. 3).
We then tested if the activation or inhibition of the
protein kinase A and protein kinase C pathways impacted
on the ability of adenosine A2A receptors to facilitate the
evoked release of acetylcholine (Fig. 4). The activation of
protein kinase A with 8-Br-cAMP (0.5 mM, n = 4) or with
forskolin (10 AM, n = 4), but not with the inactive analogue
1,9-dideoxyforskolin (10 AM, n = 2), blunted the ability of
CGS 21680 (30 nM) to facilitate the evoked release of
acetylcholine (Fig. 4A). Likewise, inhibition of protein
kinase A activity with H-89 (1 AM, n = 4) also attenuated
the ability of CGS 21680 (30 nM) to facilitate the evoked
release of acetylcholine (Fig. 4A). To further re-enforce
our conclusion that adenosine A2A receptor facilitation of
acetylcholine release depends on the activation of the
cAMP/protein kinase A pathway, we tested if the inhib-
ition of the phosphodiesterases responsible for the catab-
olism of cAMP would enhance the effect of a sub-maximal
concentration of CGS 21680. CGS 21680 (1 nM) facili-
tated the evoked release of acetylcholine by 4.4F 1.1%
(n = 3), but in the presence of the phosphodiesterase IV
Fig. 4. Ability of drugs interfering with the protein kinase A pathway and
inability of the drugs interfering with the protein kinase C pathway to
modify the adenosine A2A receptor-mediated facilitation of [
3H]acetylcho-
line ([3H]ACh) from rat hippocampal nerve terminals. The superfused
nerve terminals (142F 8 Ag protein per chamber) were stimulated twice
(S1 and S2) with veratridine (10 AM). The adenosine A2A receptor agonist,
CGS 21680 (30 nM), was present during S2 (added 7 min before S2) and
the different tested modifiers were present during S1 and S2 (added 15
min before starting sample collection) as indicated by the symbols below
each column. In (A) is shown the ability of the membrane-permeable
cAMP analogue, 8-bromo-cAMP (0.5 mM), of the adenylate cyclase
activator, forskolin (10 AM), but not of its inactive analogue, 1,9-
dideoxyforskolin (10 AM), and of the protein kinase A inhibitor, H-89
(1 AM), to attenuate the CGS 21680-induced facilitation of [3H]ACh
release. The results are meanF S.E.M. of two to four experiments.
*P < 0.05 when compared with the facilitatory effect of 30 nM CGS
21680 (first column from the left). In (B) is shown the ability of the
phophodiesterase IV inhibitor, rolipram (30 AM), to potentiate the
facilitatory effect of a lower concentration of CGS 21680 (1 nM) on
evoked [3H]ACh release. The results are meanF S.E.M. of three to four
experiments. *P< 0.05. In (C) is shown the inability of the protein kinase
C inhibitor, bisindolylmaleimide (1 AM) to modify the CGS 21680-
induced facilitation of [3H]ACh release. The results are meanF S.E.M. of
four experiments.
Fig. 3. Ability of drugs interfering with the protein kinase A or protein
kinase C pathways to affect the evoked release of [3H]acetylcholine
([3H]ACh) from rat hippocampal nerve terminals. The superfused nerve
terminals (142F 8 Ag protein per chamber) were stimulated twice (S1 and
S2) with veratridine (10 AM). The bar graph shows the ability of the
membrane-permeable cAMP analogue, 8-bromo-cAMP (0.5 mM), to
facilitate [3H]ACh release, an effect reverted by the protein kinase A
inhibitor, H-89 (1 AM), and the ability of the protein kinase C activator,
phorbol-12,13-didecanoate (250 nM), to facilitate [3H]ACh release, an
effect attenuated by the protein kinase C inhibitor, bisindolylmaleimide
(1 AM). The drugs were present either during S2 (added 7 min before S2) or
in S1 and S2 (added 15 min before starting sample collection) as indicated
by the symbols below each column. H-89 (1 AM) or bisindolylmaleimide
(1 AM) when present during S1 and S2 did not modify the S2/S1 ratio
compared with control. *P < 0.05 compared with 0%; **P < 0.05. The
results are meanF S.E.M. of four experiments.
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inhibitor, rolipram (30 AM, n = 4), CGS 21680 (1 nM) now
facilitated the evoked release of ACh by 11.2F 2.6% (Fig.
4B). Finally, the observation that the protein kinase C
inhibitor, bisindolylmaleimide (1 AM, n = 4), failed to
significantly (P < 0.05) modify the ability of CGS 21680
(30 nM) to facilitate the evoked release of acetylcholine
strongly suggests that the adenosine A2A receptor-mediated
facilitation of acetylcholine release might not depend on
protein kinase C activation (Fig. 4C).
3.3. Immunological identification of adenosine A2A recep-
tors in hippocampal nerve terminals
The pharmacological characterisation of adenosine A2A
receptors has been mostly carried out in the striatum
(Fredholm et al., 1994). To further re-enforce that hippo-
campal nerve terminals are indeed endowed with a molec-
ular entity identical to striatal adenosine A2A receptors, we
investigated by Western blot analysis if the molecular
entities recognized by adenosine A2A receptor antibodies
displayed a similar electrophoretic mobility in hippocampal
and striatal membranes. In Fig. 5 is shown a Western blot,
representative of four similar blots carried out in membranes
from different animals, demonstrating the presence in hippo-
campal nerve terminal membranes of a band of similar
apparent molecular weight (42 kDa) to that recognized in
the striatum by adenosine A2A receptor antibodies, albeit
with a much lower intensity. Control experiments showed
that the lack of addition of the primary antibody resulted in
background fluorescence in the gel (data not shown).
4. Discussion
The present study presents evidences for the presence of
adenosine A2A receptors with pharmacological and bio-
chemical features identical to these found for the prototyp-
ical adenosine A2A receptors in the striatum. In fact, we
identified by Western blot an adenosine A2A receptor-like
immunoreactivity apparently identical in the hippocampus
and striatum. Furthermore, the control by adenosine A2A
receptors of acetylcholine release from hippocampal nerve
terminals obeys the expected pharmacology for adenosine
A2A receptors (antagonism by ZM 241385 and SCH 58261
but not by DPCPX) and requires the activation of the
adenylate cyclase/cAMP/protein kinase A pathway, the
same biochemical transducing system activated by striatal
adenosine A2A receptors.
The present results are particularly important in light of
the several reports showing that the prototypical adenosine
A2A receptor agonist, CGS 21680, essentially binds to extra-
striatal regions of the central nervous system to sites
apparently different from adenosine A2A receptors (Cunha
et al., 1996, 1999; Johansson and Fredholm, 1995; Johans-
son et al., 1993; Lindstro¨m et al., 1996). The functional
demonstration of pharmacologically well-defined adenosine
A2A receptors in hippocampal neurons extends previous
demonstrations that adenosine A2A receptors mRNA is
present in the hippocampus (Cunha et al., 1994a; Dixon et
al., 1996; Peterfreund et al., 1996), namely in neurons
(Lopes et al., 2001), and constitutes a clear demonstration
that adenosine A2A receptors are not confined to the
striatum. This had already been proposed in other reports
(e.g. Barraco et al., 1995, 1996; Li and Henry, 1998; Okada
et al., 2001; Phillis, 1998; Robertson and Edwards, 1998).
However, the pharmacological and biochemical data pre-
sented in these studies do not allow distinguishing between
typical striatal-like adenosine A2A receptors and atypical
receptors and/or binding sites recognized by adenosine A2A
receptor agonists.
It is interesting to note that the cholinergic system
appears to display a well-conserved adenosine A2A recep-
tor-mediated facilitatory system in most preparations where
this has been investigated. In fact, the presence of adenosine
A2A receptors has been observed in cholinergic nerve
terminals of the striatum (Brown et al., 1990), in motor
nerve terminals (Correia-de-Sa´ and Ribeiro, 1994) and in
Torpedo electric organ nerve terminals (Satoh et al., 1997),
although in the cerebral cortex the picture is less clear (cf.
Broad and Fredholm, 1996; Phillis et al., 1993; Spignoli et
al., 1984). As we now observed in the hippocampus, the
facilitation of the evoked release of acetylcholine by adeno-
sine A2A receptors in all these systems is small in amplitude
(lower than 30%), appears to be larger in amplitude in intact
preparations than in purified nerve terminals (see Cunha et
al., 1994a; Jin and Fredholm, 1997), but always involves the
activation of the cAMP/protein kinase A pathway. Interest-
ingly, we had previously reported that the density of
adenosine A2A receptor-like binding sites and the facilita-
tory effect of CGS 21680 on acetylcholine release were
markedly enhanced in the hippocampus of aged rats (Lopes
et al., 1999b). And in these aged animals, but not in young
adult rats, we observed that CGS 21680 enhanced the levels
of cAMP (Lopes et al., 1999b), as occurs in the striatum
both in young adult and in aged rats. Also, in aged animals,
Fig. 5. Western blot identification of adenosine A2A receptors, in
membranes prepared from Percoll-purified nerve terminal membranes
obtained from the rat hippocampus (HIP) and from whole membranes of the
striatum (STR). The SDS-PAGE gel was loaded with 120-Ag protein in
each lane and is representative of four similar separations carried out with
membranes prepared from different animals.
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the control of hippocampal glutamatergic transmission is not
significantly changed by blockade of adenosine A1 recep-
tors (Cunha and Ribeiro, 2001) whereas in young adult
animals, the adenosine A2A receptor-mediated facilitation of
synaptic transmission is strictly dependent on tonic adeno-
sine A1 receptor activation (Lopes et al., 2002). Interest-
ingly, whereas adenosine A2A receptor facilitation of
hippocampal excitatory synaptic inhibition is mediated by
protein kinase C in young adult animals (Cunha and
Ribeiro, 2000b), it mostly involves activation of protein
kinase A in aged animals (Cunha and Ribeiro, 2001). Thus,
it appears that when adenosine A2A receptor-mediated
effects involve protein kinase A, then these effects become
independent of adenosine A1 receptor function, as was
presently confirmed for the adenosine A2A receptor-medi-
ated facilitation of the evoked release of acetylcholine from
hippocampal nerve terminals. It should be noted that,
although we could not find evidences for the participation
of protein kinase C on adenosine A2A receptor-mediated
facilitation of acetylcholine release in hippocampal nerve
terminals, we cannot exclude an eventual minor role of this
transducing pathway when the protein kinase A pathway is
blocked, as was reported to occur in striatal nerve terminals
(Gubitz et al., 1996).
The possible physiological role of adenosine A2A
receptors in the control of acetylcholine release in the
central nervous system is still ill-defined. In fact, with the
experimental conditions used, the predominant effect of
adenosine in cholinergic nerve terminals is to activate
inhibitory adenosine A1 receptors (e.g. Jackisch et al.,
1984), as now confirmed by the clear inhibitory effect
caused by the closest adenosine analogue, 2-chloroadeno-
sine (see also Cunha et al., 1994a; Jin and Fredholm,
1997). Only when blocking adenosine A1 receptors is it
possible to reveal an adenosine A2A receptor-mediated
facilitation of acetylcholine release (see also Cunha et
al., 1994a; Jin and Fredholm, 1997). At the motor nerve
terminals of the phrenic nerve, the elegant work of the
group of Correia-de-Sa´ et al. (1996) has provided clear
evidences that the come into play of adenosine A2A
receptors depends on the frequency of stimulation, but
this issue has not yet been tested in cholinergic pathways
of the central nervous system.
In conclusion, the present demonstration of the presence
of adenosine A2A receptors in cholinergic nerve terminals of
the rat hippocampus clearly shows that adenosine A2A
receptors are not confined to the basal ganglia in the central
nervous system.
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